- PCSK9 inhibitors are a class of lipid-lowering therapies that work by targeting the proprotein convertase subtilisin/kexin type 9 enzyme, significantly reducing LDL cholesterol levels, especially in patients unresponsive to statins
- The market growth is primarily driven by the increasing prevalence of cardiovascular diseases, growing geriatric population, and rising awareness about cholesterol management
- North America is expected to dominate the PCSK9 Inhibitorss market with a market share of 50.5%, due to advanced healthcare systems, strong reimbursement frameworks, and widespread awareness of cardiovascular disease prevention
- Europe is expected to be the fastest growing region in the PCSK9 Inhibitors market with a market share of 30.5%, during the forecast period due to rising cardiovascular disease burden and proactive government-led cholesterol screening initiatives
- Evolocumab segment is expected to dominate the market with a market share of 71.8% due to its proven efficacy in significantly lowering LDL cholesterol levels and reducing cardiovascular event risks.
